文献速递肝病

DILI住院预后评分识别特异质性药物性肝损伤住院患者不良结局风险

The DILI-Inpt Prognostic Score to Identify Hospitalized Idiosyncratic DILI Patients at Risk for Adverse Outcomes.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-11-19

基于ALFSG登记库1998-2019年305例成人特异质性DILI住院患者,构建包含总胆红素、INR、肝性脑病分级及草药膳食补充剂的DILI住院预后评分,预测21天非自发性存活(死亡或肝移植),其AUROC为0.86,优于MELD和King's College标准。

要点

  • DILI住院预后评分由总胆红素、INR、肝性脑病分级和草药膳食补充剂组成。
  • 该评分预测21天非自发性存活AUROC为0.86,优于MELD和King's College标准。
  • 研究纳入305例成人DILI住院患者,其中44例ALI、261例ALF,64%为非自发性存活。

核心结论

  • 新DILI住院预后评分可识别自发性存活可能性最低的患者。
  • 该简单预后评分若在其他队列中验证,可能有助于住院DILI患者的医疗决策。

研究设计与样本

  • 研究纳入1998年1月至2019年8月ALFSG登记库中305例成人特异质性DILI住院患者。
  • 其中44例为急性肝损伤(INR>2.0且无肝性脑病),261例为急性肝衰竭。
  • 使用入院数据构建多变量模型预测21天结局(死亡或肝移植),并与MELD和King's College Criteria评分比较。

主要发现

  • 患者中位年龄44岁,67%为女性,中位MELD评分为32(范围14-54)。
  • 可疑药物包括抗菌药(42.6%)、草药膳食补充剂(16%)和精神类药物(9.8%)。
  • 21天时110例(36%)为自发性存活,195例(64%)为非自发性存活,其中115例需肝移植、80例死亡。
  • DILI住院预后评分预测21天非自发性存活的AUROC为0.86(95%CI 0.82-0.91)。

关键数值与推荐

  • DILI住院预后评分包含总胆红素、INR、肝性脑病分级和草药膳食补充剂。
  • 21天非自发性存活定义为死亡或肝移植。

临床怎么用

  • 对住院特异质性DILI患者,可采用该评分辅助识别自发性存活可能性低、可能需要肝移植或密切监测的高危患者。
  • 该评分仅基于入院数据,简单易行,但需在其他队列中验证后才能广泛用于临床决策。

局限性

  • 研究基于ALFSG登记库数据,评分需在其他队列中验证。
  • 原文未报告评分的具体阈值和外部验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute liver failure (ALF) due to idiosyncratic drug-induced liver injury (DILI) has a poor prognosis. We set out to identify presenting features associated with nonspontaneous survival in hospitalized patients with severe idiosyncratic DILI. METHODS: A total of 305 adult ALFSG (Acute Liver Failure Study Group) registry participants from January 1998 to August 2019 had acute liver injury (ALI) (ie, international normalized ratio >2.0 without encephalopathy) or ALF attributed to DILI. A multivariable model was developed to predict 21-day outcome (death or liver transplantation) using admission data and was compared with the Model for End-Stage Liver Disease (MELD) and King's College Criteria scores. RESULTS: A total of 44 DILI patients had ALI and 261 had ALF. The median age was 44 years, 67% were female, and the median MELD score was 32 (range 14-54). Suspect agents included antimicrobials (42.6%), herbal-dietary supplements (16%), and psychoactive drugs (9.8%). At 21 days, 110 (36%) were spontaneous survivors and 195 (64%) were nonspontaneous survivors, including 115 that required liver transplantation and 80 who died. The DILI inpatient score (consisting of total bilirubin, INR, encephalopathy grade, and herbal and dietary supplement products) had an area under the receiver-operating characteristic curve (AUROC) of 0.86 (95% confidene interval, 0.82-0.91) for 21-day nonspontaneous survival that was superior to the MELD (AUROC 0.86 vs 0.79; P = .008) and King's College Criteria (AUROC 0.86 vs 0.63; P < .001) scores. CONCLUSIONS: The new DILI inpatient prognostic score identified patients with the lowest likelihood of spontaneous survival. This simple prognostic score may be a useful guide for medical decision making in hospitalized DILI patients if confirmed in other cohorts. CLINICALTRIALS: gov, Number: NCT00518440.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Likhitsup A, Su Z, Rule JA, et al. The DILI-Inpt Prognostic Score to Identify Hospitalized Idiosyncratic DILI Patients at Risk for Adverse Outcomes. Clin Gastroenterol Hepatol. 2025. PMID: 41270879. doi:10.1016/j.cgh.2025.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。